Goldman Sachs’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Goldman Sachs’s Portfolio EPRS Stock Details EPRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-16,776	Closed	-$8K	–	7468
2016 Q2	$8K	Buy	+16,776	New	+$26.9K	﹤0.01%	6895
2016 Q1	–	Sell	-16,006	Closed	-$49K	–	7696
2015 Q4	$49K	Buy	16,006 +4,342	+37%	+$19.6K	﹤0.01%	6559
2015 Q3	$52K	Buy	+11,664	New	+$68.5K	﹤0.01%	6783
2015 Q2	–	Sell	-32,046	Closed	-$287K	–	7721
2015 Q1	$287K	Buy	32,046 +21,450	+202%	+$172K	﹤0.01%	5693
2014 Q4	$60K	Buy	+10,596	New	+$55.4K	﹤0.01%	6758

Other funds holding EPRS

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Goldman Sachs's EPRS Position: Q3 2016 in Review

Goldman Sachs sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q3 2016, closing a stake of 16,776 shares — an estimated $8K sold.

Goldman Sachs first reported a position in EPRS in Q4 2014 and held it in 5 quarters. The position peaked at $287K in Q1 2015. 3 funds tracked by Wall St. Rank hold EPRS as of Q3 2016.

Goldman Sachs reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q3 2016 after selling out during the quarter.
Goldman Sachs sold 16,776 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q3 2016, an estimated $8K.
Goldman Sachs first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q4 2014 and held it in 5 quarters.
Goldman Sachs's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $287K in Q1 2015.
3 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q3 2016.

Based on Goldman Sachs's 13F filing for Q3 2016, filed 14 Nov 2016.